MesoTV: Chemotherapy + immunotherapy, another positive step in mesothelioma treatment

Drs. Anne Tsao of MD Anderson Cancer Center, Patrick Forde of Johns Hopkins, and James Stevenson of the Cleveland Clinic join Mary Hesdorffer to discuss a new clinical trial, Dream3r, a phase 3 study into the efficacy of combination chemotherapy with immunotherapy as first line treatment for mesothelioma.


Our sponsors

MesoTV is a program by The Mesothelioma Foundation. This program is made possible by our generous sponsors: Maune Raichle Hartley French & Mudd, LLC (MRHFM); Belluck & Fox; Bristol Myers Squibb; Novocure; Merck; The Gori Law Firm; Early Lucarelli Sweeney & Meisenkothen.

Related Updates & Resources